ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
You may also be interested in...
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.
As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.
Lilly wants White House Office of Management and Budget to delay final rule until there are regulatory controls against duplicate and diverted discounts. OMB has also held three meetings over past few months with organizations representing 340B providers.